Mild Cognitive Impairment with a High Risk of Progression to Alzheimer's Disease Dementia (MCI-HR-AD): Effect of Souvenaid ® Treatment on Cognition and 18 F-FDG PET Scans.
| Autor: | Manzano Palomo MS; Department of Neurology, Infanta Leonor Hospital, Madrid, Spain.; Behavioral Neurology and Dementia Group of the Spanish Society of Neurology, Barcelona, Spain., Anaya Caravaca B; Neuropsychologist, Infanta Cristina Hospital, Parla, Madrid, Spain., Balsa Bretón MA; Department of Nuclear Medicine, Getafe Hospital, Madrid, Spain., Castrillo SM; Department of Neurology, Infanta Cristina Hospital, Parla, Madrid, Spain., Vicente AM; Department of Neurology, Infanta Cristina Hospital, Parla, Madrid, Spain., Castro Arce E; Nutricia NeuroScience Medical Affairs, Madrid, Spain., Alves Prez MT; Nutricia Advanced Medical Nutrition, Madrid, Spain. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Journal of Alzheimer's disease reports [J Alzheimers Dis Rep] 2019 May 03; Vol. 3 (1), pp. 95-102. Date of Electronic Publication: 2019 May 03. |
| DOI: | 10.3233/ADR-190109 |
| Abstrakt: | Background: Previous studies have shown that Souvenaid (medical food) can have benefits on memory, cognition, and function in early Alzheimer's disease (AD) and mild cognitive impairment (MCI). Objective: Demonstrate that Souvenaid could improve or maintain cognition and has an effect on neurodegeneration biomarkers. Methods: This cohort study was carried out from June 2015 through December 2016 in the Neurology Department, Infanta Cristina Hospital, Madrid, Spain. MCI-HR-AD were recruited using Petersen criteria, neuropsychology (NPS), and 18 F-FDG PET scans to confirm the high risk of progression to dementia with one year of follow-up. Age, sex, vascular risk factors (VRF), and NPS values (Barcelona brief version) were analyzed. 18 F-FDG PET scans were analyzed as a visual procedure. The study was approved by the Research Committee of ICH. Statistical analysis was made with SPSS 22.0 version. Results: Subjects included 43 MCI patients (58.5% women; mean age 69.78±7.89): 17 receiving Souvenaid ® treatment (ST), 24 receiving no treatment (WT) and 2 who withdrew. No differences were seen in VRF, only hypercholesterolemia, and were less prevalent in the ST group ( p = 0.002). The rate of progression to dementia was 48.8% (no differences between groups, p = 0.654). A second round of 18 F-FDG PET scans showed a significance worsening of glucose metabolism in WT ( p = 0.001) versus ST, in which it was low ( p = 0.050). For NPS testing, there was a significant worsening in memory performance in the WT group ( p = 0.011) and a stabilization in ST ( p = 0.083), as well as in executive functions and attention (worsening in WT, p = 0.014). For the Subjective Changing Scale (SCS), caregivers indicated a stabilization/improvement in ST ( p = 0.017). Conclusion: Souvenaid had a significant effect on several cognitive domains, and on SCS in patients with MCI-HR-AD. Its intervention had an impact on preservation on 18 F-FDG PET scans. Competing Interests: The authors have no conflict of interest to report. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|